BCL2 and lymphoid leukemia: However, increasedexpression of the anti-apoptotic family members can sequester theBH3-only pro-apoptotic members and thus allow a cell to evade apoptosiseven in the presence of a death signal.1,2,6,7 Therefore, inhibitionof anti-apoptotic Bcl-2 proteins can restore the normal intrinsicapoptotic pathway in cancer cells, as evidenced by the FDA approvedselective Bcl-2 inhibitor Venetoclax (ABT-199) for the treatment ofchronic lymphocytic leukemia.9−11